VR-205 Met Primary Endpoint and Key Secondary Endpoints and Was Well Tolerated VR-205 Efficacy and Safety Profile in Japanese Patients Was Consistent with the Profile Observed in Global Studies Japanese New Drug Application Submission Targeted by End of 2026 June 29, 2026 -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced positive top-line results from a Phase 3 clinical trial evaluating the efficacy and safety of VR-205 (targeted-release budesonide formulation) (Nefec

The positive opinion is based on results from the Phase 3 BRUIN CLL-313 and BRUIN CLL-314 trials, previously presented at the 2025 American Society of Hematology Annual Meeting and published in The Journal of Clinical Oncology BRUIN CLL-313 is the first Phase 3 study to evaluate a non-covalent BTK inhibitor exclusively in patients with treatment-naïve CLL and BRUIN CLL-314 is the first Phase 3 CLL trial to compare non-covalent and covalent BTK inhibitors, as well as the first to compare any BTK

Deramiocel demonstrates durable skeletal and cardiac muscle benefit over five years in the HOPE-2 OLE study PUL 2.0 year-over-year decline attenuated to approximately 1 point Findings to be presented alongside previously reported HOPE-3 Phase 3 results, which met its primary and key secondary endpoints with statistical significance Deramiocel maintains a favorable safety pro both studies, with no new safety signals HOPE-2 OLE data featured in a late-breaking session; HOPE-3 in a cardiac care ses

June 26, 2026 -- Recently, the NDA for Sumecigrel Capsule (formerly known as Vicagrel), a Class 1 innovative antiplatelet drug developed by Jiangsu Vcare PharmaTech Co.,Ltd. (Vcare PharmaTech), has been officially accepted by the NMPA. The drug has now entered the NDA stage. As a global pioneer in novel antiplatelet agents, Sumecigrel is expected to provide a new and improved treatment option to tens of millions of patients with cardiovascular and cerebrovascular diseases. Sumecigrel Capsule is

Lead oral compounds demonstrated up to 25% body weight reduction with preferential fat loss, preserved lean mass, and broad metabolic improvements in DIO models June 25, 2026 -- Mwyngil Therapeutics, a biotech company focused on developing innovative small molecule therapeutics for cardiometabolic disease, today announced positive in vivo proof-of-concept results from its GPR75 inverse agonist program, supporting the potential of GPR75 modulation as a differentiated therapeutic approach for obe

June 25, 2026 -- Innovative Molecules GmbH, a late-stage clinical biotechnology company focused on the development of differentiated antiviral therapies, today announced that the first patient has been dosed in its Phase 2a clinical trial evaluating adibelivir (IM-250) for the treatment of recurrent genital herpes. The initiation of patient dosing marks a significant value-inflection point for the company and advances its lead program into proof-of-concept development. The Phase 2a study is des

Financing co-led by TCGX and ARCH Venture Partners with participation from a syndicate of premier healthcare-focused institutional investors Proceeds will support global Phase 3 trials of IBI324 (Ollin R&D code: OLN324), a potential best-in-class VEGF/Ang2 bispecific antibody, in $15 billion retina market addressing leading causes of vision loss OLN324 demonstrated faster and greater retinal drying and numerically greater vision gains versus Vabysmo® in a randomized head-to-head proof of concept

— Registration-enabling study demonstrated high clinically meaningful objective responses, achieving rapid and durable disease control — — Fanregratinib holds promise as a new treatment option for pretreated advanced ICC patients harboring FGFR2-fusions/rearrangements — June 25, 2026 -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces results from the pivotal Phase II registration study of fanregratinib (HMPL-453) in patients with intrahepatic cholangiocarcinoma (

Gilead’s Trodelvy can now be used as a monotherapy and in combination with Merck’s Keytruda to treat certain patients with triple-negative breast cancer. The FDA has given its go-ahead to Gilead’s anti-TROP-2 antibody-drug conjugate Trodelvy as a frontline option for two specific triple-negative breast cancer indications. With the approvals, announced Wednesday, Trodelvy can now be used as a monotherapy for patients with unresectable locally advanced or metastatic triple-negative breast cancer

Study met its primary endpoint, demonstrating statistically significant and clinically relevant improvements in ADHD symptoms in adults with ADHD and comorbid anxiety taking centanafadine compared to those taking placebo Centanafadine is currently under Priority Review by the FDA for the treatment of ADHD in children, adolescents, and adults, with a target action date of July 24, 2026 PRINCETON, N.J. & TOKYO--(BUSINESS WIRE)--Otsuka Pharmaceutical Development & Commercialization, Inc. and Otsuka